Treatment advice of small molecule antiviral drugs for elderly COVID-19 / 中国药理学通报
Chinese Pharmacological Bulletin
; (12): 425-430, 2023.
Article
en Zh
| WPRIM
| ID: wpr-1013933
Biblioteca responsable:
WPRO
ABSTRACT
COVID-19 has been prevalent for three years. The virulence of SARS-CoV-2 is weaken as it mutates continuously. However, elderly patients, especially those with underlying diseases, are still at high risk of developing severe infections. With the continuous study of the molecular structure and pathogenic mechanism of SARS-CoV-2, antiviral drugs for COVID-19 have been successively marketed, and these anti-SARS-CoV-2 drugs can effectively reduce the severe rate and mortality of elderly patients. This article reviews the mechanism, clinical medication regimens, drug interactions and adverse reactions of five small molecule antiviral drugs currently approved for marketing in China, so as to provide advice for the clinical rational use of anti-SARS-CoV-2 in the elderly.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Chinese Pharmacological Bulletin
Año:
2023
Tipo del documento:
Article